population. For this reason, postauthorization surveillance has assumed increasing importance in assessing less frequent side-effects and subtler differences in comparative immunogenicity of factor VIII products and in providing a real-world perspective. Indeed, some product differences have become apparent only after follow-up of 400 or more PUPs over periods of 10 years or more. [7] [8] [9] The UK National Haemophilia Database (NHD) registers and monitors all patients with severe haemophilia A as part of a prospective program of pharmacovigilance and ongoing investigation into the risk factors and potential prevention of factor VIII inhibitor development. [9] [10] [11] [12] Following market authorization of ReFacto AF (Pfizer, Walton Oaks, Tadworth Collection was supplemental to the Pfizer registry data and enabled Pfizer to secure the requisite numbers for ReFacto AF. This study was to include at least 100 consecutive UK patients treated exclusively with ReFacto AF for at least 50 exposure days (ED). In 2010, the UK National Procurement Exercise awarded 47% of the contract for supply of factor VIII to Pfizer Ltd (ReFacto AF). Consequently, 34% of UK PUPs were allocated to ReFacto AF on a contractual basis from 2010.
| ME THODS
The UKHCDO NHD was used to identify consecutive children with severe haemophilia A (<0.01 IU/L) whose first treatment was with ReFacto AF. PUPs were selected to be treated with ReFacto AF or other products non-randomly to achieve contractual volume requirements. Most large Haemophilia Centres allocate product brand to PUPs on a rotational basis but this is not universal. Patients diagnosed outside the UK were excluded because their previous treatment history was unknown.
United Kingdom Haemophilia Centre Doctors' Organisation guidelines recommend inhibitor testing of PUPS every third exposure day until 20 EDs and then every 5th ED until 50 EDs. 10 
| Statistics
Descriptive statistical analysis includes medians, interquartile ranges (IQR) and Kaplan-Meier (K-M) estimates of probabilities of inhibitor development within fifty exposure days (EDs), P(t ≤ 50), with 95%
confidence intervals (CI). Time to inhibitor development, measured in EDs, is illustrated using K-M curves. Differences in K-M curves are tested using the log rank test.
| RE SULTS
Of There was one confirmed report of a transient inhibitor, and for a further four patients, inhibitors were reported only once, and thus also considered transient. A further seven non-inhibitor patients are yet to reach 50 EDs, and three non-inhibitor patients switched products prior to 51 EDs.
Inhibitors prior to 51 EDs were identified after a median (IQR)
The seven non-switching inhibitor-free patients who have not reached 50 EDs in this study had been followed up for an estimated median (IQR) 7.5 (4.5-10. and their full follow-up has been included in the analysis.
Most patients (n = 96; Table 1 ) were of white ethnicity. Non- A further sensitivity analysis was performed to investigate the effect of the "protocol variations" described above in which five patients had been administered small amounts of other factor VIII products. When these patients were excluded, the association between high-risk mutations and inhibitors prior to 51 EDs lost statistical significance, as did the association with family history of haemophilia A.
The outcomes of the other statistical tests were unaffected. Follow-up of patients who were inhibitor-free after fifty EDs (n = 68) was available for a median (IQR) 431 (257-816) days.
TA B L E 1 Time to inhibitor by clinical and demographic characteristics
Inhibitors were detected after fifty EDs in two of these patients, after 52 and 160 EDs.
| D ISCUSS I ON
This report describes the occurrence of inhibitors in a consecutive cohort of PUPs whose first treatment was with ReFacto AF.
The incidence of inhibitors observed is comparable with previous published reports of PUP studies. [7] [8] [9] 14 The cumulative probability and using all available products. 9 There is therefore no evidence of systematic bias in allocating patients to ReFacto AF.
As expected, subjects with high-risk genotypes had significantly more inhibitors. The association between high-risk genotypes and high-titre inhibitors did not reach statistical significance, possibly because of the small numbers of patients analysed.
High-and low-titre inhibitors were detected after similar median EDs (11 in both groups). In the past, low-titre inhibitors were thought to tend to arise later than high-titre inhibitors. Our results suggest that historically later detection of low-titre inhibitors may be attributable to a sampling artefact, and that low-titre inhibitors may be detected earlier when patients are tested more frequently, as has become current clinical practice.
In conclusion, we report that in a consecutive cohort of PUPs treated with ReFacto AF in the UK the proportion developing inhibitors was similar to previous PUP studies of ReFacto AF and comparable with PUP studies of other recombinant factor VIII concentrates.
The confidence intervals around these estimates are wide, however, indicating that although there was no evidence of increased immunogenicity associated with ReFacto AF, A formal comparison of the immunogenicity of factor VIII concentrates would require a much larger sample.
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